BRIEF—Mylan and Biocon launch Semglee in the UK

Mylan and Indian development partner Biocon have launched their biosimilar insulin glargine therapy Semglee, a once-daily, long-acting basal insulin version of Sanofi's Lantus, in the UK.

The therapy was approved by the European Medicines Agency in March.

Jean-Yves Brault, Mylan’s UK country manager, said: “Insulin glargine biosimilars play a key role in the challenges faced by the NHS and offer a better value option by being able to deliver increased affordability compared with the originator insulin glargine while still offering comparable safety, efficacy and tolerability.”